Zelemiq Life Science secures £200k in seed funding to accelerate its myRipple platform development
The company raised the capital via FounderCatalyst to drive product development and validate its technology for elite sports.
Zelemiq Life Science develops non-invasive wearable technology designed to deliver continuous metabolic monitoring for athletes.
Zelemiq Life Science has secured £200k in seed funding to advance its non-invasive metabolic monitoring platform. The financing was completed through the FounderCatalyst platform.
The capital will be directed towards product development of the myRipple system, validation work within the elite sports market focusing on real-time lactate tracking, and initial commercial activities.
From the founder
"We are shifting the paradigm from 'snapshots' to a continuous 'live feed' of metabolic performance,"
Rod Lane
Co-Founder and CEO at Zelemiq Life Science
Use of funds
- 01Continue product development
- 02Invest in sales and marketing
Categories
About the company
Zelemiq Life Science
Zelemiq Life Science builds non-invasive wearable technology for real-time metabolic monitoring.